Improving the efficacy of cancer immunotherapy with modified CAR-T cells

Nov 07, 2023

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful. A limiting factor of this otherwise very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. CRC 1160 member Susana Minguet (B01) and Wolfgang Schamel (University of Freiburg) have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model. The new results have been published in the journal Nature Immunology.

More information